Cardiovascular disease (CVD) arises as a result of genetic predisposition in the context of a disease-promoting environment. While several risk factors have been identified for CVD, such as elevated serum lipid levels and hypertension, most of the genes identified thus far do not appear to involve such ‘conventional’ risk factors. Moreover, the interactions between genes and environment, such as a diet high in certain fats, adds another level of complexity to CVD and renders identification of the underlying genetic factors even more difficult. Polyunsaturated fatty acids (PUFAs), such as the ω–6 and ω–3 fatty acids, which have multiple roles in membrane structure, lipid metabolism, blood clotting, blood pressure, and, in particular, inflammation, have been linked to the reduction in CVD. Linoleic (ω–6) and α-linolenic acid (ω–3) are essential fatty acids that can be converted into long-chain PUFAs, such as arachidonic acid (AA) and eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA), respectively. These long-chain PUFAs are metabolized by enzymatically catalyzed systems via cyclooxygenases and lipoxygenases. The 5-lipoxygenase (5-LO)/leukotriene (LT) biosynthesis pathway has been biochemically and genetically associated with CVD traits in mice and humans, particularly in the context of dietary AA and EPA/DHA. In this review, we summarize the biochemical metabolism of ω–3 and ω–6 PUFAs, evaluate the evidence for genetic and nutrigenetic contributions of 5-LO pathway genes to CVD, and discuss the potential of future studies that could identify other gene-dietary interactions between PUFAs and CVD traits.
© 2009 S. Karger AG, Basel
- Cardiovascular disease
- Fatty acids
- Lusis AJ: Atherosclerosis. Nature 2000;407:233–241.
- Lusis AJ, Weinreb A, Drake TA, Allayee H: Genetics of atherosclerosis; in Topol EJ (ed): Textbook of Cardiovascular Disease. Philadelphia, Lippincott-Raven, 2002, chapter 98.
- National Human Genome Research Institute (NHGRI): A catalog of published genome-wide association studies. www.genome.gov/gwastudies (accessed 17 August 2009).
- Bezard J, Blond JP, Bernard A, Clouet P: The metabolism and availability of essential fatty acids in animal and human tissues. Reprod Nutr Dev 1994;34:539–568.
- Simopoulos AP: The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 2008;233:674–688.
- Nakamura MT, Nara TY: Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr 2004;24:345–376.
- Brenna JT: Efficiency of conversion of alpha-linolenic acid to long chain n-3 fatty acids in man. Curr Opin Clin Nutr Metab Care 2002;5:127–132.
- Wijendran V, Hayes KC: Dietary n-6 and n-3 fatty acid balance and cardiovascular health. Annu Rev Nutr 2004;24:597–615.
- Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP: Compartmental modeling to quantify alpha-linolenic acid conversion after longer term intake of multiple tracer boluses. J Lipid Res 2005;46:1474–1483.
- Jump DB: The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002;277:8755–8758.
- Leaf A, Kang JX, Xiao YF: Fish oil fatty acids as cardiovascular drugs. Curr Vasc Pharmacol 2008;6:1–12.
- Lee JH, O’Keefe JH, Lavie CJ, Marchioli R, Harris WS: Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83:324–332.
- Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ: Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008;197:12–24.
- Massaro M, Scoditti E, Carluccio MA, De Caterina R: Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids 2008;79:109–115.
- Vila L: Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med Res Rev 2004;24:399–424.
- Mori TA, Beilin LJ: Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004;6:461–467.
- Calder PC: n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S–1519S.
- Peters-Golden M, Brock TG: Intracellular compartmentalization of leukotriene biosynthesis. Am J Respir Crit Care Med 2000;161:S36–S40.
- Peters-Golden M, Henderson WR Jr: Leukotrienes. N Engl J Med 2007;357:1841–1854.
- Back M, Hansson GK: Leukotriene receptors in atherosclerosis. Ann Med 2006;38:493–502.
- Radmark O, Samuelsson B: 5-lipoxygenase: regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat 2007;83:162–174.
- Nakahata N: Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008;118:18–35.
- von Schacky C: Prophylaxis of atherosclerosis with marine omega-3 fatty acids. A comprehensive strategy. Ann Intern Med 1987;107:890–899.
- Terano T, Salmon JA, Moncada S: Biosynthesis and biological activity of leukotriene B5. Prostaglandins 1984;27:217–232.
- Mehrabian M, Allayee H: 5-Lipoxygenase and atherosclerosis. Curr Opin Lipidol 2003;14:447–457.
- Tymchuk CN, Hartiala J, Patel PI, Mehrabian M, Allayee H: Nonconventional genetic risk factors for cardiovascular disease. Curr Atheroscler Rep 2006;8:184–192.
- Mehrabian M, Wong J, Wang X, et al: Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res 2001;89:125–130.
- Mehrabian M, Allayee H, Wong J, et al: Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002;91:120–126.
- Zhao L, Moos MP, Grabner R, et al: The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004;10:966–973.
- Poeckel D, Zemski Berry KA, Murphy RC, Funk CD: Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice. J Biol Chem 2009;284:21077–21089.
- Cao RY, St Amand T, Grabner R, Habenicht AJ, Funk CD: Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis 2009;203:395–400.
- Mehrabian M, Allayee H, Stockton J, et al: Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet 2005;37:1224–1233.
- Mehrabian M, Schulthess FT, Nebohacova M, et al: Identification of ALOX5 as a gene regulating adiposity and pancreatic function. Diabetologia 2008;51:978–988.
- Spanbroek R, Grabner R, Lotzer K, et al: Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003;100:1238–1243.
- Qiu H, Gabrielsen A, Agardh HE, et al: Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006;103:8161–8166.
- Sanchez-Galan E, Gomez-Hernandez A, Vidal C, et al: Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res 2009;81:216–225.
- Wingrove JA, Daniels SE, Sehnert AJ, et al: Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet 2008;1:31–38.
- Dwyer JH, Allayee H, Dwyer KM, et al: Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004;350:29–37.
- Allayee H, Baylin A, Hartiala J, et al: Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction. Am J Clin Nutr 2008;88:934–940.
- Gonzalez P, Reguero JR, Lozano I, Moris C, Coto E: A functional Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction. Int J Immunogenet 2007;34:127–130.
- Maznyczka A, Braund P, Mangino M, Samani NJ: Arachidonate 5-lipoxygenase (5-LO) promoter genotype and risk of myocardial infarction: a case-control study. Atherosclerosis 2008;199:328–332.
- Baylin A, Kabagambe EK, Ascherio A, Spiegelman D, Campos H: Adipose tissue alpha-linolenic acid and nonfatal acute myocardial infarction in Costa Rica. Circulation 2003;107:1586–1591.
- Carlson CS, Heagerty PJ, Nord AS, et al: TagSNP evaluation for the association of 42 inflammation loci and vascular disease: evidence of IL6, FGB, ALOX5, NFKBIA, and IL4R loci effects. Hum Genet 2007;121:65–75.
- Crosslin DR, Shah SH, Nelson SC, et al: Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. Hum Genet 2009;125:217–229.
- Helgadottir A, Manolescu A, Thorleifsson G, et al: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233–239.
- Helgadottir A, Gretarsdottir S, St Clair D, et al: Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005;76:505–509.
- Girelli D, Martinelli N, Trabetti E, et al: ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study. Eur J Hum Genet 2007;15:959–966.
- Linsel-Nitschke P, Gotz A, Medack A, et al: Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is associated with myocardial infarction in the German population. Clin Sci (Lond) 2008;115:309–315.
- van der Net JB, Versmissen J, Oosterveer DM, et al: Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia. Atherosclerosis 2009;203:472–478.
- Helgadottir A, Manolescu A, Helgason A, et al: A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006;38:68–74.
- Zee RY, Cheng S, Hegener HH, Erlich HA, Ridker PM: Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 2006;37:2007–2011.
- Koch W, Hoppmann P, Mueller JC, Schomig A, Kastrati A: No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. Genet Med 2007;9:123–129.
- Assimes TL, Knowles JW, Priest JR, et al: Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Hum Genet 2008;123:399–408.
- Hakonarson H, Thorvaldsson S, Helgadottir A, et al: Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005;293:2245–2256.
- Jawien J, Gajda M, Rudling M, et al: Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 2006;36:141–146.
- Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ: Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002;22:443–449.
- Subbarao K, Jala VR, Mathis S, et al: Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 2004;24:369–375.
- Huang L, Zhao A, Wong F, et al: Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol 2004;24:1783–1788.
- Heller EA, Liu E, Tager AM, et al: Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005;112:578–586.
- Iovannisci DM, Lammer EJ, Steiner L, et al: Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: the Muscatine Study. Arterioscler Thromb Vasc Biol 2007;27:394–399.
- Freiberg JJ, Dahl M, Tybjaerg-Hansen A, Grande P, Nordestgaard BG: Leukotriene C4 synthase and ischemic cardiovascular disease and obstructive pulmonary disease in 13,000 individuals. J Mol Cell Cardiol 2009;46:579–586.
- Bevan S, Dichgans M, Wiechmann HE, Gschwendtner A, Meitinger T, Markus HS: Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations. Stroke 2008;39:1109–1114.
- Allayee H, Hartiala J, Lee W, et al: The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest 2007;132:868–874.
- Jawien J, Gajda M, Wolkow P, Zuranska J, Olszanecki R, Korbut R: The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2008;59:633–639.
- Kang JX: Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins Leukot Essent Fatty Acids 2007;77:263–267.
- Hudert CA, Weylandt KH, Lu Y, et al: Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 2006;103:11276–11281.
- Connor KM, SanGiovanni JP, Lofqvist C, et al: Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007;13:868–873.
- Berquin IM, Min Y, Wu R, et al: Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 2007;117:1866–1875.
- Mayer K, Kiessling A, Ott J, et al: Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids. Am J Respir Crit Care Med 2009;179:474–483.
Hooman Allayee, PhD
Department of Preventive Medicine, USC Keck School of Medicine
2250 Alcazar Street, CSC 206
Los Angeles, CA 90033 (USA)
Tel. +1 323 442 1736, Fax +1 332 442 2764, E-Mail email@example.com
Published online: September 23, 2009
Number of Print Pages : 9
Number of Figures : 3, Number of Tables : 2, Number of References : 69
Journal of Nutrigenetics and Nutrigenomics
Vol. 2, No. 3, Year 2009 (Cover Date: October 2009)
Journal Editor: Pérusse L. (Quebec, Que.)
ISSN: 1661-6499 (Print), eISSN: 1661-6758 (Online)
For additional information: http://www.karger.com/JNN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.